ClinicalTrials.Veeva

Find clinical trials for Melanoma in Cleveland, OH

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Non-Small-Cell Lung Carcinoma
Renal Cell Carcinoma
Lung Cancer
Squamous Cell Carcinoma

Melanoma trials near Cleveland, OH, USA:

Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma) (Mel66)

This study evaluates whether it is safe to administer a peptide vaccine made of 6MHP and a mutated neoantigen peptide (BRAF585-614-V600E) combined wi...

Active, not recruiting
Melanoma
Ocular Melanoma
Drug: CDX-1140
Drug: 6MHP

Phase 1, Phase 2

Craig L Slingluff, Jr

Cleveland, Ohio, United States and 1 other location

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma (CoMpass)

efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma...

Enrolling
Ocular Melanoma
Choroidal Melanoma
Device: Suprachoroidal Microinjector
Drug: Sham Treatment

Phase 3

Aura Biosciences
Aura Biosciences

Cleveland, Ohio, United States of America and 37 other locations

Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma

Approximately 40 participants with locally advanced or metastatic melanoma will be enrolled in 20 sites in the United States into 1 of the f...

Active, not recruiting
Locally Advanced Unresectable or Metastatic Melanoma
Drug: Selinexor
Drug: Pembrolizumab

Phase 2

Karyopharm Therapeutics
Karyopharm Therapeutics

Cleveland, Ohio, United States and 12 other locations

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

antigen (HLA)-A*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotini...

Enrolling
Metastatic Uveal Melanoma
Drug: IDE196
Drug: Nivolumab

Phase 2, Phase 3

Ideaya Biosciences

Cleveland, Ohio, United States and 62 other locations

A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma (RELATIVITY-098)

to assess nivolumab plus relatlimab fixed-dose combination (FDC) versus nivolumab alone in participants with completely resected stage III-IV melanoma...

Active, not recruiting
Melanoma
Biological: Nivolumab
Biological: Nivolumab + Relatlimab Fixed Dose Combination

Phase 3

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Cleveland, Ohio, United States and 171 other locations

A Study of APG-115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors

Part 1 is the dose escalation of APG-115 in combination with label dose of pembrolizumab.Part 2 is phase II design of APG-115 at recommended phase 2...

Enrolling
Mucosal Melanoma
Melanoma
Drug: APG-115+Pembrolizumab

Phase 1, Phase 2

Ascentage Pharma Group
Ascentage Pharma Group

Cleveland, Ohio, United States and 19 other locations

A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma (RELATIVITY-127)

not worse than nivolumab + relatlimab FDC intravenous (IV) administration in participants with previously untreated metastatic or unresectable melanoma...

Enrolling
Melanoma
Drug: Nivolumab + Relatlimab
Drug: rHuPH20

Phase 3

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Cleveland, Ohio, United States and 189 other locations

Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma (CheckMate76K)

and pediatric participants after complete resection of Stage IIB/C melanoma with no evidence of disease (NED) who are at high risk for recur...

Active, not recruiting
Melanoma
Biological: Nivolumab
Other: Placebo

Phase 3

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Cleveland, Ohio, United States and 128 other locations

A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

treatment compared to pembrolizumab in patients that have had melanoma removal surgery but are still at high risk for the recurrence of the...

Enrolling
Melanoma
Drug: Pembrolizumab
Drug: Placebo

Phase 3

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Cleveland, Ohio, United States and 195 other locations

A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Participants With Previously Untreated Advanced Melanoma. (IMCODE001)

(PROs) of autogene cevumeran (RO7198457) plus pembrolizumab compared with pembrolizumab alone in patients with previously untreated advanced melanoma...

Active, not recruiting
Advanced Melanoma
Drug: Pembrolizumab
Biological: Autogene cevumeran

Phase 2

Genentech
Genentech

Cleveland, Ohio, United States and 56 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2024 Veeva Systems